Search | IOVS | ARVO Journals

iovs

Issues
Topics
For Authors
About
- Editorial Board
- Subscriptions

Journals Home

SIGN IN

Forgot password?

Create an Account

To View More...

Purchase this article with an account.

or

Subscribe Now

Issues
Topics
For Authors
About
- Editorial Board
- Subscriptions

Narrow View

NARROW

Content Type

Meeting Abstract (4)
Journal Articles (1)

Journal

Investigative Ophthalmology & Visual Science (5)

Article Type

ARVO Annual Meeting Abstract (4)
Biochemistry and Molecular Biology (1)

Topics

Biochemistry and Molecular Biology (1)
Eye Anatomy and Disorders (1)
Immunology and Microbiology (1)
Pharmacology (1)
Retina (1)
Vitreous Disorders (1)

Tags

angiogenesis (1)
angiogenesis inhibitors (1)
electroretinography (1)
endothelial cells (1)
inflammatory markers (1)
mice (1)
oxygen (1)
peptides (1)
retina (1)
retinal diseases (1)

Specify Date Range

From: To: Apply

Showing 1 – 5 of 5

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2019

The vitreous humor from proliferative diabetic retinopathy patients: translational implications

Sara Rezzola; Mohd Imtiaz Nawaz; Anna Cancarini; Francesco Semeraro; Marco Presta

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2661. doi:

ARVO Annual Meeting Abstract June 2017

Involvement of N -formyl peptide receptors in modulating the pro-angiogenic/pro-inflammatory activity of human vitreous in proliferative diabetic retinopathy (PDR)

Mohd Imtiaz Nawaz; Sara Rezzola; Michela Corsini; Paola Chiodelli; Anna Cancarini; Daniela Coltrini; Stefania Mitola; Roberto Ronca; Mirella Belleri; Liliana Lista; Dario Rusciano; Mario De Rosa; Vincenzo Pavone; Francesco Semeraro; Marco Presta

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5209. doi:

ARVO Annual Meeting Abstract September 2016

Functional and Morphological Changes Following Macular Pucker Surgery After Topical Administration of Indomethacin 0.5%, Bromfenac 0.09%, Nepafenac 0.1%, or Placebo

Raffaele Turano; Andrea Russo; Elena Gambicorti; Anna Cancarini; Sarah Duse; Francesco Morescalchi; Ciro Costagliola; Francesco Semeraro

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):276. doi:

ARVO Annual Meeting Abstract September 2016

Comparison of visual and anatomical outcomes of half-dose photodynamic therapy and 689 nm laser treatment (pseudo-PDT) in eyes with chronic central serous chorioretinopathy.

Andrea Russo; Anna Cancarini; Elena Gambicorti; Sarah Duse; Nicolò Scaroni; Ciro Costagliola; Francesco Semeraro

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5357. doi:

Biochemistry and Molecular Biology April 2015

Antiangiogenic Effectiveness of the Urokinase Receptor-Derived Peptide UPARANT in a Model of Oxygen-Induced Retinopathy

PDF

Massimo Dal Monte; Sara Rezzola; Maurizio Cammalleri; Mirella Belleri; Filippo Locri; Lucia Morbidelli; Michela Corsini; Giuseppe Paganini; Francesco Semeraro; Anna Cancarini; Dario Rusciano; Marco Presta; Paola Bagnoli
TAGS: angiogenesis, oxygen, vascular endothelial growth factor a, inflammatory markers, endothelial cells, urokinase, angiogenesis inhibitors, electroretinography, peptides, retinal diseases, vision, vitreous body, mice, retina, urokinase plasminogen activator receptor
Invest. Ophthalmol. Vis. Sci.. 2015; 56(4):2392-2407. doi: 10.1167/iovs.14-16323

Includes: Supplemental Content

« Previous

Advertisement

Follow @ARVOiovs

IOVS Home
Issues
Topics
For Authors
About
- Editorial Board
- Subscriptions

Online ISSN: 1552-5783

Investigative Ophthalmology & Visual Science
Journal of Vision
Translational Vision Science & Technology

JOURNALS HOME
TOPICS
ABOUT ARVO JOURNALS

Copyright © 2015 Association for Research in Vision and Ophthalmology.

Forgot password?

To View More...

Purchase this article with an account.

Create an Account

or

Subscribe Now

×

×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept